Published in Med Res Rev on May 01, 2007
Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid Redox Signal (2010) 2.50
Gold nanoparticle platforms as drug and biomacromolecule delivery systems. J Control Release (2010) 1.54
Nitric oxide release: part II. Therapeutic applications. Chem Soc Rev (2012) 1.51
Molecular mediators of liver ischemia and reperfusion injury: a brief review. Mol Med (2008) 1.43
Monolayer coated gold nanoparticles for delivery applications. Adv Drug Deliv Rev (2011) 1.36
Nitric oxide release: part I. Macromolecular scaffolds. Chem Soc Rev (2012) 1.26
Nitric oxide release: part III. Measurement and reporting. Chem Soc Rev (2012) 1.23
The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov (2011) 1.21
Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor. Free Radic Biol Med (2009) 1.17
Translational research involving oxidative stress and diseases of aging. Free Radic Biol Med (2011) 1.10
Nitric oxide regulates lung carcinoma cell anoikis through inhibition of ubiquitin-proteasomal degradation of caveolin-1. J Biol Chem (2009) 1.08
Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol (2009) 1.07
Effects of slow, sustained, and rate-tunable nitric oxide donors on human aortic smooth muscle cells proliferation. Chem Biol Drug Des (2011) 1.06
Nitric oxide and cancer therapy: the emperor has NO clothes. Curr Pharm Des (2010) 1.05
Nitric oxide suppresses tumor cell migration through N-Myc downstream-regulated gene-1 (NDRG1) expression: role of chelatable iron. J Biol Chem (2011) 1.05
Oxygen/ozone as a medical gas mixture. A critical evaluation of the various methods clarifies positive and negative aspects. Med Gas Res (2011) 1.04
Role of S-nitrosylation in apoptosis resistance and carcinogenesis. Nitric Oxide (2008) 1.02
Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. Clin Exp Metastasis (2012) 1.02
Mechanisms of hepatic ischemia-reperfusion injury and protective effects of nitric oxide. World J Gastrointest Surg (2014) 1.02
JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas. Neurosurgery (2012) 0.98
The immunomodulation and anti-inflammatory effects of garlic organosulfur compounds in cancer chemoprevention. Anticancer Agents Med Chem (2014) 0.95
Photoactive Ruthenium Nitrosyls: Effects of Light and Potential Application as NO Donors. Coord Chem Rev (2008) 0.94
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci (2011) 0.94
Polymer-Based Nitric Oxide Therapies: Recent Insights for Biomedical Applications. Adv Funct Mater (2012) 0.94
Ruthenium nitrosyls derived from tetradentate ligands containing carboxamido-N and phenolato-o donors: syntheses, structures, photolability, and time dependent density functional theory studies. Inorg Chem (2010) 0.93
Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling. PLoS One (2007) 0.92
Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation. Nitric Oxide (2009) 0.90
The dual role of iNOS in cancer. Redox Biol (2015) 0.90
iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. Mol Cancer (2009) 0.89
Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis (2012) 0.85
Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles. Inorg Chem (2013) 0.85
Myeloid-derived suppressor cells: a double-edged sword? Int J Exp Pathol (2011) 0.85
Nitric oxide: perspectives and emerging studies of a well known cytotoxin. Int J Mol Sci (2010) 0.84
Biopharmaceutical applications of nanogold. Saudi Pharm J (2010) 0.83
Synthesis and chemical and biological comparison of nitroxyl- and nitric oxide-releasing diazeniumdiolate-based aspirin derivatives. J Med Chem (2013) 0.83
Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. BMC Cancer (2015) 0.83
Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas. Int J Cancer (2011) 0.82
Nitric oxide leads to cytoskeletal reorganization in the retinal pigment epithelium under oxidative stress. Adv Biosci Biotechnol (2012) 0.81
The functional role of MnSOD as a biomarker of human diseases and therapeutic potential of a new isoform of a human recombinant MnSOD. Biomed Res Int (2014) 0.81
S-nitrosylation in TNF superfamily signaling pathway: Implication in cancer. Redox Biol (2015) 0.80
T Cells and Cancer: How Metabolism Shapes Immunity. Front Immunol (2016) 0.79
Nitrosothiol Signaling in Anoikis Resistance and Cancer Metastasis. For Immunopathol Dis Therap (2012) 0.79
Can exhaled NO fraction predict radiotherapy-induced lung toxicity in lung cancer patients? Radiat Oncol (2012) 0.78
Elevated dengue virus nonstructural protein 1 serum levels and altered toll-like receptor 4 expression, nitric oxide, and tumor necrosis factor alpha production in dengue hemorrhagic Fever patients. J Trop Med (2014) 0.78
Treatment of stress urinary incontinence by cinnamaldehyde, the major constituent of the chinese medicinal herb ramulus cinnamomi. Evid Based Complement Alternat Med (2014) 0.78
Effect of Blocking of Neuropeptide Y Y2 Receptor on Tumor Angiogenesis and Progression in Normal and Diet-Induced Obese C57BL/6 Mice. Glob J Health Sci (2015) 0.78
Endothelial nitric oxide synthase gene polymorphisms and prostate cancer risk in Serbian population. Int J Exp Pathol (2013) 0.78
Nitric oxide-releasing silica nanoparticle-doped polyurethane electrospun fibers. ACS Appl Mater Interfaces (2013) 0.77
Characterization of an S-nitroso-N-acetylpenicillamine-based nitric oxide releasing polymer from a translational perspective. Int J Polym Mater (2016) 0.77
Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles. J Biol Inorg Chem (2016) 0.77
Nitrosothiol signaling and protein nitrosation in cell death. Nitric Oxide (2014) 0.77
Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI. Nitric Oxide (2013) 0.77
The implications of hyponitroxia in cancer. Transl Oncol (2014) 0.76
Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme. Cell Death Dis (2016) 0.76
Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy. J Control Release (2016) 0.75
Enzyme-responsive polymer hydrogels for therapeutic delivery. Exp Biol Med (Maywood) (2016) 0.75
Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer. Free Radic Biol Med (2015) 0.75
Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells. J Transl Med (2016) 0.75
Endothelial hypoxic metabolism in carcinogenesis and dissemination: HIF-A isoforms are a NO metastatic phenomenon. Oncotarget (2013) 0.75
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell (2017) 0.75
Disruption of tumour-host communication by downregulation of LFA-1 reduces COX-2 and e-NOS expression and inhibits brain metastasis growth. Oncotarget (2016) 0.75
Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy. Front Oncol (2017) 0.75
ATF3 reduces migration capacity by regulation of matrix metalloproteinases via NFκB and STAT3 inhibition in glioblastoma. Cell Death Discov (2017) 0.75
Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy. PLoS One (2015) 0.75
Glucocorticoids induce production of reactive oxygen species/reactive nitrogen species and DNA damage through an iNOS mediated pathway in breast cancer. Breast Cancer Res (2017) 0.75
Self-assembling soft structures for intracellular NO release and promotion of neurite outgrowth. Chem Sci (2017) 0.75
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol (2010) 4.62
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 4.36
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res (2004) 3.94
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol (2008) 3.49
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol (2010) 3.18
Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol (2007) 3.15
A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg (2008) 3.14
Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2003) 2.65
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 2.64
Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology (2008) 2.63
Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2010) 2.56
Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum (2013) 2.52
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 2.51
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A (2005) 2.49
The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res (2006) 2.36
A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg (2010) 2.27
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med (2011) 2.06
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol (2008) 1.93
Quantitative real-time PCR: a powerful ally in cancer research. Trends Mol Med (2003) 1.88
Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother (2012) 1.87
Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. J Natl Cancer Inst (2012) 1.82
Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol (2005) 1.79
Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer (2003) 1.77
Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol (2003) 1.75
Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci (2014) 1.69
Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann Surg Oncol (2011) 1.69
Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol (2009) 1.68
Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol (2008) 1.65
Control of immune response by amino acid metabolism. Immunol Rev (2010) 1.63
Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. Cell Host Microbe (2013) 1.62
Part I: Vaccines for solid tumours. Lancet Oncol (2004) 1.61
Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep (2012) 1.59
Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood (2005) 1.56
Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev (2004) 1.55
Multivisceral resection for locally advanced gastric cancer: an Italian multicenter observational study. JAMA Surg (2013) 1.53
Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol Med (2006) 1.51
Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst (2006) 1.51
Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood (2011) 1.47
Telomerase and the search for the end of cancer. Trends Mol Med (2012) 1.46
Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer (2005) 1.46
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res (2008) 1.42
Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. J Natl Cancer Inst (2004) 1.39
Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics (2013) 1.39
The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev (2004) 1.34
Role of arginine metabolism in immunity and immunopathology. Immunobiology (2007) 1.33
Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett (2008) 1.31
Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res (2005) 1.28
EUS for the staging of gastric cancer: a meta-analysis. Gastrointest Endosc (2011) 1.27
Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr Opin Immunol (2011) 1.25
Giant fibroadenoma of the breast in adolescents: report of 2 cases. J Pediatr Surg (2009) 1.24
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood (2009) 1.20
Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. Ann Surg (2011) 1.16
TNF and cancer: the two sides of the coin. Front Biosci (2008) 1.15
Gene expression profile of primary gastric cancer: towards the prediction of lymph node status. Ann Surg Oncol (2006) 1.12
Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res (2008) 1.11
Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol (2007) 1.10
Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest (2010) 1.09
Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev (2005) 1.08
Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. Eur J Immunol (2014) 1.08
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest (2015) 1.07
miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. Immunity (2013) 1.07
Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol (2011) 1.07
The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer. Ann Surg Oncol (2006) 1.07
Prospective assessment of imaging after preoperative chemoradiotherapy for rectal cancer. Surgery (2010) 1.07
-174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res (2003) 1.05
The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer (2008) 1.04
Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: a systematic review and meta-analysis. Cancer (2008) 1.04
Modulation of human T-cell functions by reactive nitrogen species. Eur J Immunol (2011) 1.03
Helicobacter pylori, inflammation, oxidative damage and gastric cancer: a morphological, biological and molecular pathway. Eur J Cancer Prev (2008) 1.02
Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol (2011) 1.02
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine (2010) 1.02
Myeloid cell diversification and complexity: an old concept with new turns in oncology. Cancer Metastasis Rev (2011) 1.01
Gastric cancer and synchronous hepatic metastases: is it possible to recognize candidates to R0 resection? Ann Surg Oncol (2014) 1.01
Retracted High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res (2012) 1.01
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res (2009) 1.00
Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker. Clin Colorectal Cancer (2009) 1.00
The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. Hum Pathol (2013) 1.00
Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol (2013) 0.99
DNA repair gene polymorphisms and risk of cutaneous melanoma: a systematic review and meta-analysis. Carcinogenesis (2009) 0.99
Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival. J Transl Med (2009) 0.99
Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res (2008) 0.99
The pros and cons of chemokines in tumor immunology. Trends Immunol (2012) 0.99
Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology (2012) 0.98
Sentinel node status prediction by four statistical models: results from a large bi-institutional series (n = 1132). Ann Surg (2009) 0.97
Metabolic mechanisms of cancer-induced inhibition of immune responses. Semin Cancer Biol (2007) 0.97
Cancer vaccines: pessimism in check. Nat Med (2004) 0.97